High Throughput Screening
In a first for the UK The Medical Technologies Innovation Facility (MTIF) is pleased to announce that its partnership with Hamamatsu Photonics UK Ltd now enables customers to have personalised demonstrations of, and access to, a novel high throughput screening tool, namely the Hamamatsu Functional Drug Screening System (FDSS) µCELL.
The FDSS/μCELL
The FDSS/μCELL is a compact, easy to use screening system that enables monitoring of GPCRs and ion channels for drug discovery and life science research. Screening various compounds at high throughput (96 / 384 well assays) is enabled by fluorescence or luminescence measurements using a highly sensitive Hamamatsu camera, which captures cell dynamics under the same conditions with no time lag between wells. It is also capable of recording changes in electrical potential in iPSC-derived neuronal and cardiac stem cells to gain a better understanding of toxic compound effects.
Features
Drug Discovery
Development of new, safe and effective medicines is enhanced when drug discovery research can be done faster and more precisely. The FDSS/μCELL monitors calcium flux and membrane potential change when adding compounds, specialised for GPCR and ion channel research, advancing early-stage innovative discoveries and accelerates research into drug solutions.
Biocompatibility
MTIF’s FDSS/μCELL can carry out assays for measuring real time production of RS as an indicator of cell health or signalling events in Biocompatibility.
About Hamamatsu Photonics UK Ltd
Hamamatsu Photonics is a world-leading manufacturer of optoelectronic components and systems. The Company’s corporate philosophy stresses the advancement of photonics through extensive research and yields products that are regarded as state-of-the-art. All products are designed to cover the entire optical spectrum and provide solutions for a wide variety of applications including analytical, consumer, industrial and medical instrumentation.